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TumorigenesisB Ligand (RANKL) is implicated as one of a number of effector molecules that
mediate progesterone and prolactin signaling in the murine mammary epithelium. Using a mouse transgenic
approach, we demonstrate that installation of the RANKL signaling axis into the mammary epithelium results
in precocious ductal side-branching and alveologenesis in the virgin animal. These morphological changes
occur due to RANKL-induced mammary epithelial proliferation, which is accompanied by increases in
expression of activated NF-kB and cyclin D1. With age, prolonged RANKL exposure elicits limited mammary
epithelial hyperplasia. While these transgenics exhibit RANKL-induced salivary gland adenocarcinomas,
palpable mammary tumors are not observed due to RANKL-suppression of its own signaling receptor (RANK)
in the mammary epithelium. Together, these studies reveal not only that the RANKL signaling axis can
programmany of the normal epithelial changes attributed to progesterone and prolactin action in the normal
mammary gland during early pregnancy, but underscore the necessity for tight control of this signaling
molecule to avoid unwarranted developmental changes that could lead to mammary hyperplasia in later life.
© 2009 Elsevier Inc. All rights reserved.Introduction
Receptor of Activated Nuclear Factor-κB Ligand (RANKL (also
known as OPGL, TRANCE, and ODF)), which is a member of the
tumor necrosis factor (TNF) superfamily, is a transmembrane trimeric
signaling ligand that mediates its downstream effects by engaging its
cognate receptor, RANK (Blair et al., 2006; Dougall and Chaisson,
2006). A member of the TNF receptor family, RANK also acts as a
homotrimer transmembrane protein which upon binding RANKL
triggers signaling cascades required for a wide variety of physiological
processes, ranging from osteoclastogenesis and bone-remodeling to T-
cell and dendritic cell survival and communication (Theill et al., 2002;
Walsh and Choi, 2003). RANKL also binds the soluble decoy receptor,
osteoprotegrin (OPG), which blocks the RANKL/RANK interaction
(Khosla, 2001).
Knockout studies in mice demonstrated an unexpected role for
RANKL and its receptor RANK in parity-induced mammary morpho-
genesis and function (Fata et al., 2000). Absence of RANKL or RANK
resulted in a marked attenuation in mammary alveologenesis
resulting in a lactational defect at parturition (Fata et al., 2000). This
mammary phenotype shares many similarities with the previouslyl rights reserved.described progesterone receptor knockout (PRKO), prolactin knockout
(PRLKO) and prolactin receptor knockout (PRLRKO) mammary
phenotypes (Brisken et al., 1999; Horseman et al., 1997; Lydon et al.,
1995; Oakes et al., 2008), suggesting a connection between RANKL,
progesterone, and prolactin signaling during parity-induced mam-
mary morphogenesis. In support of this proposal, molecular studies
demonstrate that RANKL can be induced in the murine mammary
epithelium by progesterone or prolactin exposure (Fata et al., 2000;
Mulac-Jericevic et al., 2003; Srivastava et al., 2003). Moreover, in the
case of progesterone, recent microarray studies reveal mammary
RANKL transcription can be rapidly induced by short-term progester-
one treatment (Fernandez-Valdivia et al., 2008), suggesting that
RANKL may be required for early progesterone-dependent prolifera-
tive changes which occur in the mammary epithelium of the parous
animal. Further support for this supposition is the observation in the
hormone-treated ovariectomized mouse model that mammary
RANKL induction is restricted to PR positive luminal epithelial cells
which are segregated from (but in close apposition to) a subset of PR
negative cells that express cyclin D1 and proliferate in response to
progesterone (Mulac-Jericevic et al., 2003).
Notwithstanding the growing evidence supporting RANKL as a
mediator of progesterone and prolactin-induced mammary morpho-
genesis, we are still uncertain as to the extent to which RANKL
functionally contributes to these morphogenetic events at the gross
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further exacerbated by an increasing number of seemingly unrelated
mediators that have also been ascribed to PR and/or PRLR action in the
mammary epithelium (Brisken et al., 2002, 2000; Fernandez-Valdivia
et al., 2008; Harris et al., 2006; Naylor et al., 2005; Satoh et al., 2007).
To address the above, we have used a transgenic approach to
evaluate the response of themammary epithelium of the virginmouse
to RANKL exposure. It's important to note that although the parous
RANKL (and RANK) knockout mouse demonstrated that absence of
RANKL signaling results in impairments in alveologenesis, the direct
effects of RANKL on mammary epithelial cell biology were not fully
explored. Furthermore, our transgenic approach was used to deter-
mine whether continuous (or inappropriate) RANKL expression in the
virgin mammary gland leads to adverse developmental consequences
such as hyperplasia and neoplastic transformation. The latter question
is important since in other physiological contexts RANKL signaling has
been shown to underlie a number of aberrant cellular processes,
which include proliferation and survival, programmed cell-fate,
intercellular communication as well as cell-migration. The perturba-
tion of such cellular functions has been linked to the etiology and/or
progression of such clinicopathological disorders as malignant bone
disease and metastasis, humoral hypercalcemia of malignancy, and
prostate cancer (Chen et al., 2006; Farrugia et al., 2003; Hansen et al.,
1999; Jones et al., 2006).
Here, our transgenic studies reveal that the RANKL signaling axis
alone can trigger both precocious ductal side-branching and alveolar
budding within the simple ductal structure of the pubescent and adult
virgin mammary gland. These epithelial changes are the very
processes that are abrogated in the PRKO, PRLKO, and PRLRKO
mammary gland (Brisken et al., 1999; Horseman et al., 1997; Lydon
et al., 1995; Oakes et al., 2008). The underlying cause of these
morphological changes results from accelerated RANKL-induced
mammary epithelial proliferation, which is paralleled by an upregula-
tion in the pleiotropic transcription factor Nuclear Factor-κB (NF-κB)
as well as cyclin D1. Despite this proliferation, however, RANKL
transgenics do not exhibit mammary tumors. One plausible explana-
tion for the lack of mammary tumor formation is the observed
suppression by RANKL of mammary RANK expression, the net result of
which is to curtail RANKL action. Interestingly, in other developmental
systems in which RANKL-induced RANK downregulation is not
observed (i.e. in the salivary epithelium), RANKL initiated epithelial
hyperplasia and neoplastic transformation is free to progress.
Collectively, our ﬁndings support the proposal that, despite a growing
number of effectors assigned to mammary PR and PRLR action, the
RANKL signaling cascade may represent a critical mediator of the
normal mammary epithelial response to progesterone and prolactin
signaling during early pregnancy and that tight control of this effector
molecule is required to avoid unwarranted hormone-induced mam-
mary epithelial expansion.
Materials and methods
Generation of MMTV RANKL transgenic mouse lines
The full-length (2.221 kb) murine RANKL cDNA (GenBank
accession number: AF013170) was directionally inserted (with the
aid of an Xba1 and Not1 linker) into a unique EcoR1 site within exon 3
of the rabbit β-globin gene which comprises part of the MMTV-KCR
transgene construct (Ma et al., 1999). In addition to exon 3, theMMTV-
KCR construct also contains a short segment of exon 2, full-length
intron 2 as well as the polyadenylation signal of the rabbit β-globin
gene. Prior tomicroinjection into male pronuclei of single-cell (FVB/N)
embryos and subsequent transfer to pseudopregnant ICR recipients
(Harlan Sprague Dawley Inc., Indianapolis, IN), the Xho1 excised
MMTV-RANKL transgene (4.9 kb) was isolated from the pBluescript KS
ll cloning vector (Stratagene, La Jolla, CA). Founders (and progenypositive for the transgene) were identiﬁed by PCR before further
characterization by Southern blot analysis. As indicated in Fig. 1A, the
PCR primers (1: 5′-GAAAATGTACTATAGTTTATCAGCC-3′; and 2: 5′-
GTCAAGGCTTTTCTATGGAATAAGG-3′) ﬂank the junction between the
3′ untranslated region (UTR) of the RANKL cDNA and exon 3 of the
rabbit β-globin gene to generate an amplicon of 489 bp in size; this
amplicon was also used as a transgene speciﬁc probe for Southern
analysis (Figs. 1B, C). For these studies, mice were maintained as
hemizygotes for the transgene in a FVB/N genetic background using
stock mice from The Jackson Laboratory, Bar Harbor, ME. In the case of
salivary tumor studies, palpable salivary tumors were allowed to reach
1.0 cm in diameter before transgenic animals were euthanized for
histological and molecular analysis.
All mice were maintained in a temperature controlled (22±2 °C)
environment, 12-h light, 12-h dark photocycle, and fed rodent chow
meal (Purina Mills Inc., St. Louis, MO) and fresh water, ad libitum.
Surgical procedures as well as experimental and euthanasia protocols
were approved by the Institutional Animal Care and Use Committee of
Baylor College of Medicine and were in accordance with the
procedures outlined in the “Guide for Care and Use of Laboratory
Animals” (NIH publication 85–23).
Histological analysis
For immunohistochemical analyses, tissueswere ﬁxed overnight in
Bouin's ﬁxative or 4% paraformaldehyde; for immunoﬂuorescence
detection, tissues were ﬁxed in 4% paraformaldehyde for 2 h.
Immunohistochemistry and dual-immunoﬂuorescence were per-
formed as described previously (Mukherjee et al., 2006). The
following primary antibodies were used in these studies: rabbit
anti-human PR (DAKO Corporation, Carpinteria, CA, (A0098; 1:100));
goat anti-mouse RANKL (R&D Systems Inc., Minneapolis, MN, (AF462;
1:200)); goat anti-mouse RANK (R&D Systems Inc., (AF692; 1:100));
mouse anti-BrdU (Amersham, Piscataway, NJ, (1:50 dilution)); mouse
anti-human alpha-actin (Sigma-Aldrich, St. Louis, MO, (A2547;
1:100)); mouse anti-human cytokeratin 8 (Fitzgerald Industries
International, Inc., Concord, MA, (RDI1038; 1:40)); rabbit anti-
human cyclin D1 (Lab Vision Corporation, Fremont, CA, (RB-9041-
P0; 1:40)); and rat anti-mouse Mac-3 (BD Biosciences, San Jose, CA,
(550292; 1:200)). For dual-immunoﬂuorescence analysis, tetra-
methyl-rhodamine isothiocyanate -conjugated streptavidin (red
color) and ﬂuorescein isothiocyanate (green color) were used to
ﬂuorescently simultaneously detect two proteins in situ; full instruc-
tions are detailed in the Tyramide Signal Ampliﬁcation (TMA)
Fluorescence Kit (NEL701; Perkin Elmer Life Sciences, Boston, MA)
as well as in (Ismail et al., 2002; Mukherjee et al., 2006). Slides were
washed and mounted in Vectashield mounting medium with 4′, 6′-
diamidino-2-phenylindole (DAPI; Vector Laboratories, Inc., Burlin-
game, CA). Sections were viewed with an Axioplan 2 microscope
equipped for epiﬂuorescence detection with appropriate ﬁlters for
tetramethyl rhodamine isothiocyanate and ﬂuorescein isothiocyanate
detection (Carl Zeiss, Jena, Germany). For Supplemental Fig. 2,
immunopositive cells (single or double immunopositive) were
quantitated from 1000 DAPI stained luminal epithelial cells in three
separate histological sections per mouse; ﬁve mice per genotype were
analyzed. Results are expressed as percentagemean±SEM; differences
were considered signiﬁcant (at Pb0.05) by Student's t test (Fernan-
dez-Valdivia et al., 2008; Lydon et al., 1995). Digital images were
captured with Metavue Software 4.6r9 (Universal Imaging Inc.,
Downingtown, PA); ﬁnal image composites were constructed with
Photoshop CS3 (Adobe Systems, Inc., San Jose, CA).
To quantitate 5-bromo-2-deoxyuridine (BrdU) incorporation (as
detected by immunohistochemistry (Fig. 3J)), mice were injected
(intraperitoneally) with BrdU (Amersham Biosciences, NJ) at 0.1 ml/
10 g of body weight, 2 h prior to sacriﬁce. Tissues were ﬁxed,
processed, parafﬁn-embedded, and sectioned as described (Lydon et
Fig. 1. Generation of RANKL transgenic mouse lines. (A) Full-length murine RANKL cDNAwas inserted into a unique EcoR1 site within the MMTV-KCR construct. Southern analysis of
TG founders: P21, 5813, and 5816 is shown in (B) and (C); FVB denotesWTsiblings. (B) Digestion of genomic DNAwith XhoI, which releases the transgene from the genome, shows the
predicted 4.9 kb hybridizing band in all transgenics. (C) To estimate the number of transgene integration sites, Southern blot of Hind-III-digested genomic DNA revealed that most of
the transgene integrates into one locus with fewer integrants in other loci (asterisks); note, line P21 displays the highest copy number for the transgene. (D) Using RNase Protection
Assay (RPA), mammary transcript levels for RANKL in lines: P21; 5813; and 5816 were compared to WT (FVB). Marker lanes are denoted by “M”, whereas P− and P+ indicate
riboprobes for RANKL (233 bp) and cyclophilin (150 bp) in the absence or presence of RNase respectively. The black arrow highlights the position of the protected fragment for RANKL
(205 bp) whereas the grey arrow shows that for cyclophilin (100 bp); TG lines P21 and 5813 were expanded for further analysis. (E) RPA of RANKL expression was conducted on
multiple tissues obtained from lines P21 and 5813. Lanes 1–9 indicate RNA from mammary gland, uterus, salivary gland, heart, spleen, kidney, liver, intestine, and lung. Along with
mammary gland (lane 1), note the high level of expression of the transgene in lung tissue of line P21 (lane 9) and in the salivary gland of both lines (lane 3).
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from 1000 cells in three separate histological sections per mouse (as
above); six mice per genotype were examined. Final counts were
expressed as a mean percentage (±SEM) of total epithelial cells
counted. Note: representative sections were used in these studies in
which only intensely stained nuclei were scored positive. For whole-
mount staining, inguinal mammary glands were processed as
previously described (Lydon et al., 1995).
To quantitate Mac-3 positive macrophages per mm2 of lung
tissue (Supplemental Fig. 3), three WT mice and an equal number of
RANKL transgenic (TG) siblings were used. Six random photographs
were taken (at 40X) per mouse (18 photographs taken per
genotype). Cells scoring immunopositive for Mac-3 were quantitated
per ﬁeld (0.53 mm2). Counts were averaged and standard deviation
(SD) calculated; statistical signiﬁcance was determined by Student's
t test.
Molecular analysis
For Western blot analysis, protein extracts were prepared from
isolated mammary epithelial cells according to (Moraes et al., 2007).
Protein (10 μg) was resolved by 4–15% gradient sodium dodecyl
sulfate-polyacrylamide gel electrophoresis before transfer to poly-
vinylidene diﬂuoride membranes (Bio-RAD Laboratories, Hercules,
CA). The following primary antibodies (at 1:1000 dilution) were used:goat anti-mouse RANKL (R&D Systems Inc., MN, (AF462)); goat anti-
mouse RANK (R&D Systems Inc., (AF692)); goat anti-human β-actin
(Santa Cruz Biotechnology Inc., Santa Cruz, CA, (sc-1616)); rabbit anti-
human cyclin D1 (Lab Vision Corporation, CA, (RB-9041-P0)); rat anti-
mouse OPG (R&D Systems Inc., MN (MAB459)); rabbit anti-mouse
phospho AKT (Cell Signaling Technology Inc., Danvers, MA, (3031));
rabbit anti-mouse AKT (Cell Signaling Technology Inc., MA, (9272));
rabbit anti-human phospho-NFκB (p65; Ser 536) (Cell Signaling
Technology Inc., MA (3031)); rabbit anti-rat NFκB (Cell Signaling
Technology Inc., MA (3034)). Following incubation with the appro-
priate secondary antibodies, immunoreactive bands were visualized
using an enhanced chemiluminescence substrate detection kit (Pierce
Biotechnology, Rockford, IL).
The RNase protection assay (RPA) was performed using the RPA III
kit according to the manufacturer's instructions (Ambion, Inc., Austin,
TX); total RNA isolation was performed using the TRIzol extraction
method (Invitrogen Corporation, Carlsbad, CA). For each tissue, total
RNA from three mice per test group was pooled for RPA and the assay
performed three times with different mice in each assay. The RANKL
riboprobe template (catalog #: 51-559661 (TRANCE)), which gives a
protected probe length of 205 nucleotides (nt) and an unprotected
probe length of 233 nt, was custom made by BD Biosciences
PharMingen, San Diego, CA; this probe was previously described
(Mulac-Jericevic et al., 2003). Southern blot analysis was followed
according to our previously described procedures (Lydon et al., 1995).
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Generation of the MMTV-RANKL transgenic mouse
To determinewhether the RANKL signaling axis alone can program
the mammary epithelium to elicit many of the morphological changes
attributed to mammary PR and PRLR action during early pregnancy, a
mouse mammary tumor virus (MMTV) transgenic approach was
employed to target full-length transmembraneous RANKL (of murine
origin) to the mammary epithelium of the virgin mouse (Figs. 1A–C).Fig. 2.Whole-mount analysis reveals precocious ductal-side branching and alveologenesis in
4-week-old WT (A, C), whole-mount analysis reveals that the age-matched RANKL TG exh
(arrows)). In all cases, the pubertal TG gland exhibits numerous terminal end buds (arrow
branched epithelial network in the adult. While the 8-week-oldWT virgin displays a simple d
D) is accentuated by 8 weeks-of-age (F, H), presumably due to the cumulative effects of recu
panel C and (G) apply to (D) and (H) respectively; LN denotes the lymph node, a structuralTheMMTV RANKL transgenic is referred to as “TG” from hereon. Based
on the level of RANKL transgene expression in the mammary gland
(approximately 2.5 fold over endogenous levels found in the
mammary gland of the WT pregnant mouse (Supplemental Fig. 1)),
two TG lines (P21 and 5813) were expanded for further analyses (Fig.
1D). Both lines also express transgene-derived RANKL in other tissues,
including the salivary gland and lung (Fig. 1E). The RPA results shown
in (Figs.1D and E) are representative of ﬁvemice per genotype. For the
results in Figs. 1D and E, tissues were harvested for total RNA isolation
from 12 week-old virgin mice.the mammary gland of the pubertal and adolescent RANKL TG mouse. Compared to the
ibits extensive ductal side-branching and the emergence of lateral alveolar buds (B, D
heads) that result from multiple bifurcations in quick succession, leading to a more
uctal architecture (E, G), the precocious alveologenesis observed in the 4week-old TG (B,
rrent ovarian cycles. Scale bar in panel A applies to panels (B), (E), and (F). Scale bars in
reference point in the inguinal gland.
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side-branching and alveologenesis at puberty
While both TG lines develop normally to adulthood and exhibit
normal reproductive function, whole-mount analysis reveals overt
mammary ductal side-branching and alveologenesis at puberty (Fig.
2). Compared to the mammary gland of a 4 week-old wild-type (WT)
sibling (Figs. 2A and C), the TG gland displays signiﬁcantly more
terminal end buds and clear evidence of nascent ductal side-branchesFig. 3. The mammary epithelium of the adult virgin exhibits signiﬁcant proliferation in respo
does not express RANKL (A (arrow)), the age-matched TG (both lines) exhibit robust RANKL e
is shown in panel B whereas a transverse section through TG alveoli is shown in panel C. DA
apply to (D) and to ((C), (E), and (F)) respectively. Immunohistochemistry for BrdU incorporat
(I)). In this ﬁeld, a few scattered cells score positive for BrdU incorporation in theWTgland ((G
be detected in ductal transverse sections ((H) arrow) as well as in longitudinal sections of alv
cells scoring positive for BrdU in the duct (black bar) and alveolar bodies (white bar) fromWT
an increase of 3–4 fold in the number of cells scoring positive for BrdU incorporation is o
negligible number of alveolar structures in the WT at this age). The counts are expressed a
Unlike WT (K), the increase number of BrdU positive cells in the TG gland is also accompani
apply to (I) and (L) respectively.in subtending ducts (Figs. 2B and D). The increased number of
terminal end buds, ductal side-branches, and emergent alveolar buds
observed in the 4 week-old TG results in a more complex arborated
ductal network in the 8 week-old TG mammary gland as compared to
the age-matched WT gland (Figs. 2E–H). Together, our whole-mount
studies show that activation of the RANKL signaling axis results in
morphogenetic changes in the pubertal gland that are normally
associated with mammary progesterone and prolactin action during
early pregnancy (Fernandez-Valdivia et al., 2005).nse to the RANKL signal. While the mammary epithelium of the 16 week-old WT virgin
xpression in the mammary epithelium ((B, C) arrow); a longitudinal section of a TG duct
PI images in panels (D–F) correspond to (A–C) respectively; scale bars in panels A and B
ion is shown for mammary glands from theWT virgin (G) and age-matched TG ((H) and
) arrow). In contrast, numerous luminal epithelial cells registering positive for BrdU can
eolar lobules ((I) arrow) of TG mammary glands. The percentage of mammary epithelial
and TG are displayed as a histogram shown in panel J. In response to RANKL expression,
bserved in the ductal and alveolar epithelium of the TG gland (as expected, there is a
s the mean percentage of cells positive for BrdU incorporation±SEM; n=6 mice/group.
ed by extensive lateral budding along the ducts ((L) arrow). Scale bar in panels H and K
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mouse
Mammary RANKL expression in the WT mouse is only induced in
the luminal epithelial compartment during early to mid-pregnancy
and attenuates as pregnancy progresses to term (Gonzalez-Suarez et
al., 2007). Although RANKL is not normally observed in the mammary
epithelium of the 8 week-old WT adult virgin (Fig. 3A and (Gonzalez-
Suarez et al., 2007;Mulac-Jericevic et al., 2003)), immunoﬂuorescence
reveals transgene-derived RANKL is expressed in most (but not all)
luminal epithelial cells in the mammary epithelium of the TG sibling
(Figs. 3B and C). By this age, the TG gland exhibits numerous alveolar
bodies (Figs. 3B and C (white arrow)) which are not observed in the
WT gland (Figs. 3A and D). Furthermore, transgene-derived RANKL is
correctly targeted to the cell membrane (Figs. 3B and C). Importantly,
transgene-derived RANKL expression in the luminal epithelial
compartment is coincident with a marked increase in cellular
proliferation (Figs. 3G–J). The increased number of ductal and alveolarFig. 4. RANKL is targeted to both PR positive and negative luminal epithelial cells in the ma
positive for dual immunoﬂuorescence for RANKL (green) and PR (red) within the mammary g
16-week-old RANKL TG virgin (B), RANKL expression is targeted to both PR positive and neg
PR+RANKL+, and PR+RANKL− respectively). Like the mammary gland of the 5.5 day pregnant
positive for BrdU expression (red arrow). Note that in panels C and D the majority of Brd
(indicated by green arrow). However, a small number of cells are positive for both BrdU and R
(E) Compared toWT, phospho NF-κB and cyclin D1 protein expression is increased in the ma
Lanes 1–3 in the WT and TG group represent mammary epithelial cell protein isolates fr
immunoblots in which different mice were used in each case.epithelial cells undergoing proliferation in the TG gland results in a
highly ﬂorid ductal morphology which is not observed in the WT
gland (compare Figs. 3K with L). These results underscore the critical
importance of RANKL initiated epithelial proliferation in the morpho-
logical changes that occur in the mammary gland of the TG mouse.
The RANKL signal is targeted to both PR positive and negative luminal
epithelial cells of the RANKL transgenic mammary gland
In the case of the WT mouse, the mammary gland at early
pregnancy expresses RANKL in the luminal epithelial compartment
with a spatiotemporal expression pattern coincident with mammary
PR expression (Fig. 4A (white arrow)). These results concur with our
previous observations using hormone-treated ovariectomized mice
(Mulac-Jericevic et al., 2003). In the case of the adult virgin RANKL TG
mammary gland, RANKL expression is observed in over 40% of luminal
epithelial cells irrespective of whether they are positive or negative for
PR expression ((Fig. 4B) and Supplemental Fig. 2). Similar to the WTmmary gland of the RANKL transgenic mouse. (A) White arrow indicates a cell scoring
land of the early pregnant (5.5 days) WTmouse. However, in the mammary gland of the
ative mammary epithelial cells (green, white, and red arrows indicate cells PR−RANKL+,
WT mouse (C), the mammary gland of the 16-week-old TG virgin shows numerous cells
U positive cells (indicated by red arrow) are segregated from cells expressing RANKL
ANKL expression in the TG gland ((D) white arrow); scale bar in panel A applies to (B–D).
mmary gland of the 16 week-old RANKL TG virgin (β-actin represents a loading control).
om individual mice of the same age; the results are representative of three separate
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RANKL transgenic mammary epithelium contains numerous cells
undergoing proliferation as evidence by cells scoring positive for BrdU
incorporation (Fig. 4D). The majority of BrdU positive mammary
epithelial cells in the TG gland represent a separate cell-type from
RANKL positive cells, suggesting RANKL still projects most of its
proliferative inﬂuence through a paracrine signaling pathway(s).
However, compared to the WT parous gland (Fig. 4C), the TG gland
displays a marked increase in the number of cells that score positive
for both RANKL expression and BrdU incorporation (Fig. 4D (white
arrows) and Supplemental Fig. 2); suggesting an autocrinemechanism
also underpins RANKL action in the TG gland. This is to be expected
since RANKL is indiscriminately targeted to the TG mammary
epithelium. In agreement with the histological data shown in Fig.
4D, Western analyses conﬁrms that signaling pathways involved in
cellular proliferation (i.e. NF-κB/cyclin D1 (Cao et al., 2001)) are
induced in the mammary epithelium of the RANKL TG (Fig. 4E).
Interestingly, we have previously shown that mammary PR also
induces cyclin D1 (Said et al., 1997). Together, these observations
suggest that PR may induce cyclin D1 expression in part through
activation of the RANKL signaling axis. Noteworthy, both activation of
pro-survival pathways (i.e. as measured by increases in phospho-
protein kinase B/AKT) and increased nuclear translocation of Id2—
cellular processes previously attributed to mammary RANKL action
(Fata et al., 2000; Kim et al., 2006)—are not observed in the RANKL TG
gland (data not shown). In addition, CCAAT/enhancer-binding protein-Fig. 5. The RANKL signal results in mammary hyperplasia with age in the nulliparous RANKL
and age-matched TGs (C–F are representative of TG lines P21 and 5813 respectively) show e
panels B, D, and F represent higher magniﬁcations of regions indicated by arrows in panels A
and local areas of hyperplasia indicated by the arrows in panels D and F. Scale bar in panelsβ (C/EBP-β) and β-casein, which have also been shown to be
mammary RANKL targets in-vitro (Kim et al., 2002), were not
increased in the TG mammary gland (data not shown).
Persistent RANKL exposure induces limited mammary epithelial
hyperplasia in the nulliparous transgenic mouse
Considering RANKL induces mammary epithelial proliferation in
the RANKL TG, we next asked whether this proliferation facilitates
mammary hyperplasia in later life. Whole-mount examination of
mammary glands from nulliparous RANKL TG (at ∼10 months-of age)
revealed the location of small areas of limited hyperplasia usually at
the distal tips of medial ducts (Fig. 5); this phenotype is exhibited by
mouse lines from both RANKL TG founders (P21 and 5813). However,
unlike the salivary gland (see Fig. 8), the mammary epithelium of the
RANKL TG does not undergo neoplastic transformation. In combina-
tion with data shown in Fig. 4, our ﬁndings show that, despite release
from hormonal control, RANKL continues to mediate most of its
proliferative effects through a paracrine mode of action. The results
also demonstrate that RANKL induced mammary epithelial prolifera-
tion is attenuated to the point that extensive mammary hyperplasia
and subsequent tumorigenesis fails to manifest with time. These
results also suggest that morphological changes that occur in the
RANKL TG virgin gland rely heavily on proliferative pathways that at
least include induction of cyclin D1 and most likely other parallel
signaling cascades that have yet to be identiﬁed.TG mouse. Whole-mounts of mammary glands obtained from 10-month-old WT (A, B)
vidence of hyperplasia only in the TG mammary glands (C–F (arrow)). Images shown in
, C, and E respectively. Compared to WT (B), notice the extensive ductal side-branching
A and B apply to (C, E) and (D, F) respectively (LN denotes lymph node).
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transgenic mouse
Unlike the RANK transgenic (Gonzalez-Suarez et al., 2007), our
RANKL TG can generate a functional lactating mammary gland at least
after a ﬁrst pregnancy (Fig. 6). However, examination of mammary
tissue from the lactating RANKL TG reveals localized areas of
proliferation (Figs. 6A and B). Apart from being hyperproliferative,
most cells within these regions express high levels of RANKL (Figs. 6C
and D); suggesting clonal expansion of a RANKL positive cell-lineage.
Furthermore, dual immunoﬂuorescence reveals that a signiﬁcant
number of these cells score positive for both RANKL expression and
BrdU incorporation (Figs. 6E and F), suggesting that RANKL maintains
the proliferative status of these regions mainly through an autocrine
mode of action. Following a ﬁrst pregnancy, approximately 5–10% of
the mammary epithelium of the lactating RANKL TG comprises these
proliferative foci, whether these regions expand and become
neoplastic with recurrent pregnancies is currently being examined.
Long-term RANKL exposure attenuates RANK mammary expression
Although RANKL is not expressed in the pubertal WT mammary
gland, low-levels of RANK expression are detected by immunoﬂuor-
escence (Fig. 7A). While RANK is weakly expressed in most cells of the
mammary luminal epithelial compartment of the WT virgin (Fig. 7A),Fig. 6. RANKL continues to induce epithelial proliferation in the mammary gland of the lac
mammary gland of the lactating RANKL transgenic (arrowhead). (B) These epithelial region
(arrowhead). Most cells in these hyperproliferative foci express transgene derived RANKL (C
immunoﬂuorescence shows thatmost cells in these regions are positive for RANKL expression
BrdU respectively). (F) The white arrowhead indicates a cell positive for RANKL expression (g
respectively.the signaling receptor is not detected in the myoepithelial or stromal
compartments. Marked RANK expression is detected in the mammary
epithelium of the WT pregnant mouse (Fig. 7B); however, this
expression is signiﬁcantly decreased at lactation (Fig. 7C). These
results concur with recent immunohistochemical studies by Gonza-
lez-Suarez et al. (2007). Highermagniﬁcation reveals that themajority
of RANK expression is localized to the apical–lateral region of the
luminal epithelial cell in the virgin WT mammary gland and of cells
comprising the ductal epithelium of the early pregnant mouse (Figs.
7D–F). Although RANK expression in the RANKL TG mammary gland
spatiotemporally parallels that of WT, the level of RANK expression is
signiﬁcantly decreased in the TG gland (Figs. 7G–I). Western analysis
conﬁrms the marked reduction of RANK expression in the RANKL TG
mammary gland (Fig. 7J). In contrast, the expression level of
osteoprotegrin (OPG; the third member of the RANKL signaling triad
(Khosla, 2001)) is not altered in the RANKL TG mammary gland (Fig.
7J). These ﬁndings agree both with recent in-vitro studies showing
chronic RANKL exposure down-regulates RANK expression as well as
with immunohistochemical investigations which found that mam-
mary RANK expression decreases following RANKL exposure during
pregnancy (Gonzalez-Suarez et al., 2007). Although breakdown in
RANKL control of RANK expression has yet to be associated with
severe abnormal mammary growth responses that lead to neoplastic
progression, other epithelial systems (i.e. salivary gland (see below))—
in which RANKL suppression of RANK expression is not observed—tating RANKL TG mouse. (A) Foci of undifferentiated epithelial cells are detected in the
s contain numerous cells undergoing proliferation as evidence by BrdU incorporation
and D show these cells stained with DAPI and for RANKL expression respectively). Dual
and BrdU incorporation (E and F show these cells stained with DAPI and for RANKL plus
reen) and for incorporated BrdU (red). Scale bar in Panels C and E apply to panels D and F
Fig. 7. RANK expression is signiﬁcantly attenuated in the RANKL TG mammary gland. Immunoﬂuorescence (IMF) detection of mammary RANK expression is shown for the 8-week-
old WT virgin (A), late pregnant ((B) 18.5 days), and lactating ((C) day 7) WT mouse (red IMF indicated by the red arrow). Nuclei of all cells in each ﬁeld are detected by blue staining
with DAPI. Note RANK expression in the virgin and late pregnant mouse with attenuated expression at lactation. A higher magniﬁcation of a region in the image shown in (A) is
displayed in (D–F): DAPI staining (D), RANK IMF (E), and themerged image (F) are shown. The red arrow showsmammary RANK expression is predominantly apical in the virgin. DAPI
staining and RANK IMF in the mammary gland of the age-matched TG is shown in panels G and H respectively. Note the attenuated signal for RANK in the TG gland (H) compared to
WT (E); (I) is the merged image of (G) and (H). Scale bars in panels A and D apply to (B, C) and (E–I) respectively. (J) Western analysis conﬁrms that RANK expression is signiﬁcantly
reduced in the TG mammary gland. While OPG levels are equivalent between the WT virgin and age-matched TG, RANK expression is markedly reduced in the TG gland; β-actin is a
loading control. Each lane represents mammary epithelial cell protein isolate from an individual mouse in the WT and TG groups; the immunoblot shown is representative of four
immunoblots in which different mice were used in each case.
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plastic transformation. Whether down-regulation of mammary RANK
expression occurs at the transcriptional or post-translational level has
yet to be determined.
The RANKL signal induces salivary gland adenocarcinomas
Although palpable mammary tumors have yet to be reported for
the RANKL TG, multifocal salivary tumors are readily detected bymanual palpation in this model within one year (Figs. 8A–C). Tumors
are classiﬁed as poorly differentiated adenocarcinomas which origi-
nate mostly from acinar cells of serous and mucinous lobules within
the submandibular salivary gland (tumors were not observed in the
parotid or sublingual glands). Histopathological features usually
consisted of large polygonal tumor cells with a high nuclear to
cytoplasm ratio. The round to ovoid nucleus of tumor cells was
consistently pleomorphic, hyperchromatic, and frequently contained
mitotic ﬁgures (data not shown). Unlike the salivary gland of the adult
Fig. 8. RANKL induces salivary adenocarcinomas. (A) An 11 month-old nulliparous RANKL TG exhibits two palpable salivary tumors in the submandibular region (arrowheads). With
H&E staining, a tumor section shows an undifferentiated adenocarcinoma ((B) white arrowhead delineates border between normal and tumor tissue); black arrowhead highlights a
normal excretory duct. A Kaplan–Meier survival curve reveals that by one year-of-age most of the RANKL TG group exhibit palpable salivary tumors (C); only females were examined
in this study. Inset in panel C shows the typical gross morphology and size of a surgically resectioned salivary tumor. Dual immunoﬂuorescence for the myoepithelial marker K-14
(red) and RANKL (green) reveals K-14 expression demarcating the salivary acinar bodies in the WT salivary gland ((D) white arrow (nuclei are stained blue by DAPI)); however,
salivary RANKL expression is not detected at this stage of development. The preneoplastic RANKL TG salivary gland shows transgene-derived RANKL (green) is expressed in luminal
epithelial cells of the acinar compartment ((E) white arrowhead)). Epithelial cells of neoplastic TG salivary tissue express high levels of RANKL (F). Dual IMF for RANKL (green) and
BrdU (red) in the TG salivary tumor shows proliferating cells are positive (white arrow) and negative (red arrow) for RANKL (green) expression (G); DAPI stain of section in panel G is
shown in panel H. Scale bar in (D) applies to (E–H). (I) Western analysis of TG salivary tumors reveal increased levels of RANK, phospho NF-κB, cyclin D1, and phospho AKT with
concomitantly decreased levels of OPG expression. Each lane in the WT and TG group correspond to mammary epithelial cell protein isolates from an individual mouse of the same
age; this immunoblot is representative of four separate immunoblots in which different mice were used in each experiment.
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preneoplastic submandibular salivary tissue of the RANKL TG (Fig. 8E
(white arrows)). With neoplastic progression, the majority of tumor
cells of submandibular adenocarcinomas express RANKL in the TGmodel (Fig. 8F (white arrow)). Interestingly, the majority of tumor
cells undergoing proliferation are separate from tumor cells that
express RANKL (Figs. 8G and H); suggesting that a paracrine
mechanism underlies RANKL induced proliferation in this tumor
137R. Fernandez-Valdivia et al. / Developmental Biology 328 (2009) 127–139context. Unlike the TGmammary gland (Fig.7), RANK expression is not
suppressed by RANKL in the salivary gland tumor (Fig. 8I). Moreover,
OPG expression is signiﬁcantly reduced in the TG salivary tumor as
compared toWTsalivary tissue (Fig. 8I) whichmay also accentuate the
phenotype; OPG is known to block the engagement of RANKL with
RANK (Khosla, 2001). As expected, both proliferative and pro-survival
pathways controlled by RANKL are signiﬁcantly induced in the RANKL
TG salivary tumor. Apart from demonstrating that persistent expres-
sion of RANKL and its receptor, RANK, is causal for epithelial
hyperplasia that leads to tumorigenesis, our salivary gland studies
also raise the question of whether normal RANKL signaling has a role
in the normal development and/or function of this tissue (similar to
the mammary gland, the salivary gland undergoes branching
morphogenesis during early development (Tucker, 2007)). In addition
to palpable salivary tumors, the RANKL TG mouse also presents overt
lung inﬂammatory lesions (Supplemental Fig. 3). This observation is
not unexpected since RANKL, which can act as proinﬂammatory
cytokine (Maruyama et al., 2006), was found to be targeted to lung
tissue in these TG mice (Fig. 1E).
Discussion
Both transcriptional and immunohistochemical studies (Fata et al.,
2000; Mulac-Jericevic et al., 2003; Srivastava et al., 2003) implicate
RANKL as one of a number of parallel and perhaps interconnected
signaling cascades which execute proliferative and pro-survival
programs obligate for progesterone and prolactin-induced mammary
morphogenesis in the early pregnant mouse. In the context of
progesterone signaling, RANKL is only induced in the luminal
epithelial compartment of the murine mammary gland during early
to mid-pregnancy (Gonzalez-Suarez et al., 2007) and exclusively in PR
positive cells (Fig. 4A). The deﬁned spatiotemporal expression pattern
for RANKL (along with PR) suggests that this signaling molecule may
comprise a paracrine communication pathway which has been
proposed for progesterone-induced mammary morphogenesis
(Fernandez-Valdivia et al., 2005). Strict spatiotemporal control of
mammary RANKL expression by PR (and PRLR) is expected since
dysregulation of RANKL signaling in other physiological systems has
been shown to result in malignancies, metastases, and unwarranted
inﬂammation (Theill et al., 2002; Walsh and Choi, 2003). Also, the
observation that alteration in the normal expression levels of RANKL
molecular targets (i.e. NF-kB and cyclin D1) is linked to mammary
hyperplasia further supports this expectation (Brantley et al., 2001;
Wang et al., 1994).
Here, our transgenic studies reveal that introducing RANKL alone
into the mammary epithelium of the virgin results in precocious
ductal side-branching and alveologenesis in the pubescent murine
mammary gland. The observation that activation of the RANKL
signaling cascade alone in the virgin mammary epithelium elicits
many of the morphological changes attributed to PR and PRLR action
during early pregnancy suggests a prominent role for RANKL among
the increasing number of mediators currently assigned to PR and/or
PRLR in this tissue (Brisken et al., 2002, 2000; Fernandez-Valdivia et
al., 2008; Harris et al., 2006; Ismail et al., 2004; Naylor et al., 2005;
Satoh et al., 2007). Although a number of activating pathways have
been attributed to transduce the mammary RANKL signal, up-
regulation of activated NF-κB and cyclin D1 may represent critical
effectors in eliciting these early structural changes. However, it's
important to note that other as yet unidentiﬁed RANKL signaling
pathways may also be required for these morphological responses.
Surprisingly, however, the level of mammary epithelial prolifera-
tion observed in the pubescent and young adult RANKL transgenic is
not maintained or accentuated with age. Attenuation in the mammary
RANKL signaling response in the nulliparous RANKL TG is due to
down-regulation of RANK by transgene-derived RANKL expression,
suggesting that RANKL suppression of its own signaling receptor mayconstitute a normal control mechanism for RANKL action during
parity-induced mammary morphogenesis. This supposition is sup-
ported by the observation that mammary RANK expression attenuates
following RANKL exposure in the parous mouse, Fig. 7 and (Gonzalez-
Suarez et al., 2007). Interestingly, progesterone ligand also suppresses
its own nuclear receptor in the mammary epithelium (Fernandez-
Valdivia et al., 2008; Ismail et al., 2002) and dysregulation of this
control mechanism has been linked to aberrant mammary epithelial
growth responses (Poole et al., 2006; Shyamala et al., 2000, 1998).
By contrast, however, RANKL suppression of RANK expression is
not observed in the salivary epithelium of these animals. In this
physiologic context, unfettered RANKL signaling results in epithelial
hyperplasia which results in aggressive adenocarcinomas with time.
Although these observations underscore the importance of simulta-
neous expression of RANKL and RANK in the onset and/or promotion
of epithelial hyperplasia and neoplastic transformation, the mechan-
ism(s) by which RANK evades RANKL-dependent downregulation in
the salivary epithelium has yet to be determined.
Unlike the RANK transgenic (Gonzalez-Suarez et al., 2007), our
RANKL transgenic does not display an overt lactational defect. In the
case of the RANK transgenic, overexpression of RANK during
pregnancy induces a marked increase in mammary epithelial
proliferation and survival with an inhibition of terminal differentia-
tion (Gonzalez-Suarez et al., 2007). In this animal model, transgenic-
derived RANK (as well as endogenous RANK) is activated by hormone-
induced RANKL which reprograms the mammary epithelium toward
proliferation rather than differentiation. With our RANKL transgenic,
transgene-derived RANKL down-regulates the ﬁnite amount of
endogenous RANK that is induced during mid-pregnancy thereby
attenuating the RANKL response. Similar to the RANK transgenic,
however, the mammary epithelium of the lactating RANKL transgenic
exhibits regions of hyperproliferation which are positive for RANKL
expression. Within these regions, a signiﬁcant number of proliferating
cells are RANKL positive, suggesting an autocrine mechanism under-
pinning RANKL-induced proliferation in this context, clearly at odds
with the paracrine mechanism suggested for RANKL during normal
parity-induced mammary morphogenesis (Fig. 4). Interestingly, a
switch from a paracrine to an autocrine regulatory loop for estrogen/
progesterone induced mammary epithelial proliferation has been
implicated as an early cellular event in hormone-dependent breast
tumors in the human (Clarke et al., 1997). Whether these hyperpro-
liferative regions expand with recurrent pregnancies to result in a
lactational defect or neoplastic transformation is currently being
explored.
In summary, our studies have employed transgenesis to assess the
relative importance of a presumptive effector molecule for mammary
PR and PRLR action in vivo. By virtue of its ability to recapitulate many
of the PR and PRLR dependent morphogenetic changes that occur
during early pregnancy, the RANKL signaling axis is proposed to act as
a key mediator of mammary PR and PRLR action. However, it's
important to note that this proposal has not been directly tested in the
transgenic studies described here. Clearly, determining whether
transgenic-derived RANKL can “rescue” the PRKO or PRLRKO mam-
mary phenotype would directly test this proposal. Unfortunately,
attempts to “rescue” the PRKO mammary phenotype with transgene-
derived RANKL (through generation of a MMTV-RANKL/PRKO bigenic)
were unsuccessful due to inactivity of the MMTV-LTR in the PRKO
mammary cell-lineage (data not shown). Although this transgenic
“rescue” approach has been feasible with other versions of MMTV-LTR
(Hiremath et al., 2007), we believe a more powerful “rescue” method
is to use the PRKO-reverse tetracycline-dependent transactivator
(rtTA) knockin mouse (Mukherjee et al., 2007). The PRKO-rtTA
knockin model is designed to enable doxycycline-induced expression
of RANKL speciﬁcally in the mammary cell-lineage of the PRKO that
would have expressed PR in the wild-type mammary gland (these
studies are currently ongoing). In addition to the above “rescue”
138 R. Fernandez-Valdivia et al. / Developmental Biology 328 (2009) 127–139experiments, we believe the next critical research objectives in this
understudied area of mammary gland development will be to: (1)
determine themechanism(s) bywhich RANKL controls the availability
of its signaling receptor; (2) codify the full-spectrum of downstream
effector pathways that are regulated by the mammary RANKL signal;
(3) deﬁne how progesterone and prolactin (Fata et al., 2000;
Srivastava et al., 2003) coordinately regulate mammary RANKL
expression; and (4) establish whether dysregulation of RANKL
signaling is involved in the early stages of hormone-induced aberrant
epithelial expansion in the human mammary epithelium that could
lead to hyperplasia and neoplasia.
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